Progenity Inc at Raymond James Human Health Innovation Conference (Virtual) Transcript
Good morning, everyone. Thanks for joining us at the Raymond James Human Health Innovation Conference. I'm Andrew Cooper, and I cover diagnostics here for Raymond James.
And we are excited and happy to have Progenity joining us this morning. The Company is in the midst of a little bit of a transition here, exiting the genetic testing market -- or reproductive health market a little bit to focus on the pipeline that's really exciting, most immediately in -- with its preeclampsia rule-out test that I'm sure we'll talk about. And then really some interesting assets in drug delivery and sampling and testing in a pill-based platform, primarily targeting the GI and GI tract initially.
So I'm joined by CEO, Harry Stylli; and CFO, Eric d'Esparbes. (Conference Instructions) Maybe to start, I'm going to turn it over to Harry just to give us a little bit of flavor on where you were, where you are today, what's changed over the last few months that led to this decision to make a little bit of a transition, and what has you most excited
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |